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INTRODUCTION

Extensive cross reactivity among the parainfluenzamumps-NDV group of myxoviruses has been observed in man and
experimental animals.

These observations have

led

to great

confusion concerning the relationships between these viruses,
since variation is seen in different individuals and in
different animal species.

The observation of heterologous

antibody production against members of this group other than
the virus shown by isolation to be the infective agent has
led

to misgivings concerning the serologic diagnosis of

infection with these agents.

A still unanswered question

is whether heterologous antibody represents de novo production
of that antibody in an individual, or is an anamnestic response
seen only in individuals with previous experience with the
virus to which heterologous response is evoked.

The question

arises as to whether these viruses share common structural
antigenic components, as is the case with the influenza viruses.
In the present study experiments were conducted to
characterize the primary, secondary and heterologous antibody
responses with regard to 19S and JS antibody production in
monkeys inoculated with mumps and/or DA virus.

In addition,

absorption of sera with viral antigens was carried out to
determine if heterologous antibody v/ould react with the
antigen which had caused its increased production.
Elucidation of the nature of heterologous antibody
response is important for understanding the basic relation-

2

ships of members of this group.. Furthermore, the understanding
of these interrelationships is necessary for evaluation of
serologic response in clinical diagnostic and epidemiologic
studies.

The possible role of the heterologous response as

protective mechanism against viral infection is worthy of
consideration.

REVIEW OF LITERATURE

General Consideration of Myxoviruses with Special Reference
to the Parainfluenza-Mumps-NDV Group
The name myxovirus was suggested in 195^ to classify
those viruses which could be related to Influenza A virus on
*3

the basis of physical,

chemical and biological properties, ~

The criteria for inclusion in this group are: l) ability to
hemagglutinate fowl erythrocytes, 2) presence of viral receptor
destroying enzyme,

3) removal of erythrocyte receptors by

receptor-destroying enzyme of vibrio cholerae filtrate, 4)
removal of "normal inhibitor" from serum by receptor-destroying
enzyme,

5) growth in amnionic cavity of chick embryo, 6) size

of 80-150 mu , 7) sensitive to ether, 8) stable

o

.

-70 C, 9) ENA virus.

when stored at

In addition to the influenza viruses,

mumps virus and Newcastle Disease virus (NDV),

several other

viruses which meet the criteria of myxoviruses have been
isolated from man and animals; these are grouped together as
the parainfluenza viruses.
The parainfluenza viruses have been isolated from many
geographic areas, from several host species, and have been
found associated with a variety of clinical states.

These

viruses were originally named for place of isolation, various
biological properties, host species or individual, or associated
clinical syndrome.

This lead to a diverse nomenclature for a

group of related viruses,

some strains of which seemed identical.

Andrewes et al. suggested name parainfluenza and proposed
those viruses which would make up the first three members of

this group.'"

Accordingly, parainfluenza-1 includes Sendai

(hemagglutinating virus of Japan) and hemadsorption type-2
(HA-2) viruses, parainfluenza-2 includes croup-associated (CA)
virus, and parainfluenza-3 includes hemadsorption type-1 (HA-l)
Parainfluenza-4 was isolated in 1959 from adults and

virus.

children with respiratory illnesses.

32

The name parainfluenza-5 has been proposed for a group of
23

viruses,

commonly found in captive simian populations and recently

in humans,

including DA virus and SA virus.

2k 45
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The original

human isolation of DA virus was accomplished by Hsiung et al.
from a patient with infectious hepatitis.

?4

It was demonstrated

that this myxovirus was antigenically indistinguishable from
SV-5 found in monkeys.

Studies have shown many cross reactions between different
parainfluenza viruses.

These viruses have also been shown to

cross react with mumps virus and NDV.

As will be enumerated

below the cross reactions occurring among these viruses are
far from consistent, varying from species to species and from
individual to individual.

The close relationship of mumps

and KDV to the parainfluenza viruses was recognized by Andrewes
et al., but because of wide acceptance of the existing names
for these viruses they were not considered as parainfluenza
viruses.

L

Furthermore,

clinically these two viruses are not

associated with respiratory illnesses which are characteristic
of symptomatic infection with the parainfluenza viruses.
Numerous studies have failed to demonstrate any cross reactivity
between any of the strains of influenza and the parainfluenza,

5

mumps or Newcastle Disease viruses.

>

^4, jjO,40

therefore

seems reasonable to consider parainfluenza-mumps-NDV to be a
group of related myxoviruses, distinct from the influenza
viruses.

Distribution of Parainfluenza Antibodies in Human Populations
Several serological surveys of populations from around the
world have indicated that these viruses are ubiquitous and that
the incidence of antibodies to each virus is similar in the
different areas studied.

LaPlaca and Mosovivi studied a large

number of sera from India,

Italy and Colorado.

They found

86-97.5$ positive reactors to parainfluenza-3, 60-80$ to
parainfluenza-1 and 8-22$ to parainfluenza-2.'"1

In New Haven

a study of 304 hospitalized patients showed the following
incidences of positive serologic reactions: parainfluenza-1,
54$; parainfluenza-2, 63$; parainfluenza-3, 83$; DA virus,
74$; and mumps, 70$.c

Chanock found 90$ of young adult males

he tested to have antibody against parainfluenza-2.1

A study

of residents of southern Louisiana showed prevalence of
antibodies against these viruses to be: 75$ for parainfluenza-3,
37$ for parainfluenza-2,

19$ for HA-2 and 9$ for Sendai virus.""

Clinical States Associated with Parainfluenza-Mumps-NDV Infections
in Man
The parainfluenza viruses have been most commonly isolated
from children and adults with respiratory illnesses.

The most

common symptoms are rhinnorhea, fever and cough, occassionally
symptoms of pneumonia are seen.

43

The most serious condition

definitely known to be caused by these agents is viral croup

6
in infants and young children.

8 10 21 52

’

’

These agents,

particularly parainfluenza-1, are the most common cause of
croup in children under 2 years old.

The clinical syndrome

of parotitis caused by mumps is well known.

Newcastle Disease

virus infection has rarely been documented in humans, and then
only in association with mild conjunctivitis.

^5

The serological

studies cited above would indicate all of these viruses,

except

NDV, are associated with high incidence of subclinical infection.
In a study by Horstmann and Hsiung, parainfluenza-2 virus was
isolated from three cases of sudden unexplained death of infants.

21 52

This suggests that these viruses may be associated with serious
sequelae in infants.
Parainfluenza Virus Infections in Animal Populations
The viruses of the parainfluenza-mumps-NDV group are also
widespread among domestic animal populations.

Parainfluenza-3

is the etiologic agent for "shipping fever" in cattle, a
respiratory illness manifested only when cattle are crowded.

1 20 57
’
’J1

Seventy per cent of cattle slaughtered in the United States have
antibody to parainfluenza-3.

2

Parainfluenza-3 has recently been

isolated from fatal cases of pneumonia occurring in patas monkeys
crowded after transportation from Africa to England.

12

The

monkeys were shown to acquire parainfluenza-3 after captivity,
and the virus isolated was similar to that found in humans.
Hsiung has reported 791<> of monkeys arriving in New Haven to
have parainfluenza-3 antibodies.

23

DA virus is very common in

captive monkeys, but antibody against this virus which is
identical to the simian virus, SV-5> is rare in wild monkeys.

2k

’

7

This evidence suggests that parainfluenza-3 and -5 may be
acquired by susceptible animals after they are brought into
contact with human environment.

Incidence of antibody

against these viruses in laboratory animals received in New
Haven was determined by Hsiung et al.

Monkeys, rabbits and

guinea pigs had high incidence of antibody against all members
of this group except NDV, hamsters had only DA antibodies, while
mice and chickens had none.

23

It is important to keep these

data in mind when evaluation experiments utilizing laboratory
animals.

Cross Beactivity Among the Parainfluenza-Mumps-NDV Group
Cross Beactivity in Man:

In 1956. Chanock isolated CA virus

(parainfluenza-2) from infants with croup.

At this time he

noted that four of eight patients with mumps showed a
heterologous rise in HI anitbody to this newly isolated
myxovirus.1

Subsequently, Chanock et al. studied two separate

acute episodes of febrile illness in nursery schools, in one
parainfluenza-1 was shown to be the etiologic agent and in the
other parainfluenza-3.

Heterologous antibody rise was seen in

both populations to the non-infecting one of these two viruses
with 33$ involved in the parainfluenza-1 outbreak having
parainfluenza-3 rise, whereas 12$ of the other group showed
heterologous rise.

Most of those with heterologous response had

had pre-existing antibodies.

The viruses which were isolated

produced no heterologous response in hamsters without pre-existing
antibody.The greater incidence of heterologous parainfluenza-3
antibody was believed due to greater previous experience with this

3

virus.

An earlier study by Chanock of children with respiratory

illnesses found no heterologous rise to parainfluenza-1 or -2
or mumps and only 1 in 10 with parainfluenza-1 had a rise to

8
parainfluenza-3.
The patient in whom the original isolation of parainfluenza-4
was made showed heterologous response to parainfluenza-3, but
not parainfluenza-1 or -2.

It has been shown that adults, but

not children, have heterologous response to mumps when infected
Op

with parainfluenza-4. ~

Cross reactivity with parainfluenza-5 in humans is poorly
understood.

Chanock concluded the low number of individuals

with CF antibody to SV-5 had this as a result of infection with
parainfluenza-2.

Q

He concluded, that there is no evidence

for human infection caused by this agent.

Evidence is cited

above that DA virus indistinguishable from SV-5 can cause human
infection.

25

The antigenic relationship between mumps and NDV has been
observed since 1949.

In this case previous experience with

NDV is presumed to be unnecessary for the commonly observed NDV
antibody found in patients convalescent from mumps, and it is
believed naturally occurring NDV antibody in the population is

83

the result of mumps infections. "

The close relationship of

these two viruses is borne out by common biological properties
of hemolysin activity^ and their proximity on the erythrocyte
receptor gradient.

42

DeMeio and Walker found 22 of 24 young adult patients
with clinical mumps to have heterologous antibody rise to

9

parainfluenza-1.

They also found positive correlation between

antibodies to parainfluenza-1 and mumps in sera from well
medical students.

From these findings they concluded,

"It

is quite likely that much, and perhaps most, of the antibody
against HVJ (parainfluenza-l) found in the general population
of the United States is attributable to mumps virus infection
rather than actual experience with HVJ.”

J

In the years since

this study, parainfluenza-1 has been shown to be a common
respiratory pathogen in the United States.

11 21

3

Heterologous

responses to parainfluenza-2 and -3 have also been noted in
mumps patients.1

Lennette et al.

studied sera from 47 mumps

patients and found 40$ heterologous rise to parainfluenza-1,
21$ to parainfluenza-3, and 8$ to parainfluenza-2.

They found

the incidence of heterologous response to increase with age.

40

These workers along with others previously cited propose that
in order for a heterologous antibody response to occur among
the parainfluenza and mumps viruses, pre-existing antibodies
9 16
It is of note that in the instances cited,'1

must be present.

demonstration of cross reactivity lead to the false conclusion
that parainfluenza-1 and -5 were not a frequent cause of human
infection in certain populations with antibodies against these
agents.
Hsiung et al.

studied antibody response in 10 patients

in whom parainfluenza viruses were isolated.
reactions were seen in these patients.

Extensive cross

Most puzzling among

these patients was a 1 month old infant who had no titer to
parainfluenza-1,

-2, -3, mumps or DA when parainfluenza-2 was

10
isolated; however, 3 months later had antibody to all of these
viruses demonstrated.

25

Cross Reactivity in Experimental Animals:

Animal experiments

have in general showed extensive cross reactivity among these
viruses similar to that seen in human studies with some
differences according to the species used.

Chanock et_ ai.

showed that guinea pigs which have parainfluenza-3 antibodies
will have an increase in this antibody when inoculated with
mumps or parainfluenza-1, whereas all animals without pre¬
existing parainfluenza-3 antibodies and some with them failed
to show this heterologous response.

8

Cook et al.

found

individual guinea pigs to show different heterologous responses
which indicated relationships between: parainfluenza-1 and -2;
parainfluenza-1 and -3;

parainfluenza-3 and mumps.

14

Using

chicken and guinea pig immune sera prepared against parainfluenza-1,
mumps and NDV, Ishida et al.
these viruses.

27

1

showed cross reactivity between

Similar relationships between these viruses

have been shown using rabbit immune sera.'5"'

Hamsters inoculated

with parainfluenza-3 showed no anitbody rise to parainfluenza-1
or -2, or mumps. J ')
Heterologous antibody responses to inoculation with mumps
and DA virus in different species of laboratory animals was
carried out by Hsiung.

Only animals without antibodies to

mumps and DA were used.

Babbits developed mumps antibody

after DA inoculation, but only showed specific response to mumps
inoculation.

Guinea pigs showed heterologous response to both

viruses, whereas hamsters showed only specific antibody rise.

11

Chickens had heterologous rise to parainfluenza-3 and HDV
(they had previous inoculation with NDV) after mumps or DA.
Monkeys inoculated with DA virus showed heterologous response
to mumps and parainfluenza-3, and rarely to parainfluenza-1 or
-2.

Hsiung considered the possibility that the animals had

previous contact with the viruses to which they showed a
heterologous rise since these responses were seen in those
species which had high incidence of natural infection.

23

Studies of Antibody Structure
Antigen-Antibody Absorption:

Absorption of antibodies by viral

particles is one method of demonstrating the presence of
structural antigenic components shared by more than one virus.
A known specific viral antigen is added to serum, antigenantibody complexes are allowed to form, and the virus particles
(with any attached antibody) are removed from the mixture.

Serum

is tested for antibody against those viruses in which common
components are suspected before and after the absorption
procedure.

A decrease in titer of antibody against a virus

other than that used for the absorption is evidence of common
antigen shared by these two viruses.

Removal of viral particles

from the serum mixture is accomplished by ultracentrifugation
or absorption onto erythrocytes, the latter being limited to
those viruses which exhibit hemagglutination.
Using antibody absorption techniques, Jensen and Francis
have determined that k2 strains of Influenza A share 18 antigenic
2Q
components. y

Clarke has shown common antigens shared by Group B

12

arborviruses.^
In the only published report of absorption analysis of the
parainfluenza-mumps-M)V group, Hsiung found only homologous
antibody was removed by DA virus and parainfluenza-3 antigen.
In this study sera was used from a chimpanzee which had been
inoculated with DA virus had shown an antibody rise to DA,
parainfluenza-1 and -3, and mumps.

23

Jensen et al. have shown that

certain strains of influenza virus will not absorb antibody to
parainfluenza-1.^
Determination of 19S and 7S Components:

In recent years it has been

noted that two types of antibody, differing in molecular size, are
formed in response to antigenic stimulus.

A macroglobulin with

sedimentation coefficient of 19 Sverberg units (19S) appears in
the initial phase of a primary response.

Later smaller globulin,

7S, appears and persists for long periods of time.

5

This smaller

antibody seems to be the important measurable factor in the
"immunological memory system."

A secondary response is characterized

by rapid production of large amounts of 7S antibody, formerly
thought without production of 19S.

Svehag and Mandel have shown

that in rabbits inoculated with polio-virus about

50 times as much

antigen is required to cause JS production as 19S production, and
that if doses of antigen insufficient to induce 7S production are
used a secondary response on reinoculation will not occur.

A8

Further

they have shown that the secondary response, in their test system,
is characterized by a production of 19S antibody similar to that
seen in the primary response.

49

The JS antibody

13

responded to secondary stimulus with a rapid 200-fold increase
so that 19S, present in much smaller quantities,

could only be

detected when separated from 7S by ultracentrifugation.

Svehag

and Mandel also cite evidence that cessation of 19S, 4-5 days
after inoculation appears due to loss of antigenic stimulus
which is necessary for continued 19S production, but not JS
production once it is initiated.

49

They postulate two different

cell populations produce these different types of antibody.

The

conclusions of Svehag and Mandel are in aggreement with those
of Uhr and Finkelstein who studied the immunologic response
of rabbits inoculated with bacteriophage.

50

Separation of 19S and 7S is accomplished by differential
centrifugation across a density gradient of sucrose or cesium
chloride.''

It has been found that 2-mecaptoethaftol

will destroy activity of 19S but not 7S antibody.'
been shown to occur by breaking disulfide
macroglobulins.

17

(2-ME)
This has

bonds in the

Treatment of serum with 2-ME is a useful

way of determining presence of 19S antibody; however,

it will

show decrease of antibody titer only if 19S makes up a large
part of the antibody present.

The relative insensitivity of

this technique accounts for the conclusion reached by some that
there is no production of 19S in a secondary antibody response

41,51

MATERIALS AND METHODS

Virus Strains
Mumps.

Two strains of mumps virus were used.

One strain

(DD^) was obtained from Dr. Werner Henle who had isolated it from
a patient in 195^*

Isolation was in Hela cell tissue culture,

and it was passed four times before storage at -70°C.

Before

use in these experiments the virus was passed six times by
amniotic inoculation of 6 day old chick embryos, the fluid
being harvested after 7 days.
ml.

The fluid contained 10

7

EID per

The second strain used was Enders strain mumps virus.
DA Virus.

Tissue culture fluid from monkey kidney tissue

cultures infected with DA virus (Eh-32rj)* was used.

The fluid

6 5
contained 10 *' TCID per ml.
Parainfluenza-3.

Parainfluenza-3 (Ph-10)*was grown in

monkey kidney tissue culture in the presence of SV-5 antisera.
The fluid contained 10^*^ TCID per ml.

Animal Inoculations
Monkeys ft1-k.

Four rhesus monkeys were inoculated with

mumps virus, numbers 1 and 3 via the parotid duct as described
O 1

by Johnson and Goodpasture^

and numbers 2 and ^ by instillation

of the inoculum into the nasopharynx.

One ml. of inoculum

containing 10' EID of DD^ strain mumps virus was given to each
animal.
After inoculation the animals were watched daily for signs
of illness.

There were no changes in temperature, parotid size

or consistancy, or in eating pattern to indicate illness.
* Number of passages in rhesus tissue culture

15

Attempts to isolate mumps virus from saliva and urine were
Saliva was collected 2, h, 6, 8,

carried out.

after inoculation and urine on days 6 and l4.

11 and 14 days
The saliva was

collected with a sterile cotton swab which was pulverized in
1.5 ml. of Hanks balanced salt solution containing 150 mg.
streptomycin and 150 units penicillin.

One-tenth ml. of urine

was put into 1.5 ml. of the same Hanks solution.
were cleared by centrifugation.

These samples

Of each sample in Hank’s

solution 0.1 ml. was inoculated into each of three 6 day old
chick embryos and 0.2 ml. into each of three 3 day old chick
embryo fibroblast cultures.

The egg fluids were harvested

after 5 days and checked for hemagglutination of 0.5$ chick
erythrocytes.

The fluids from each group of three eggs were

pooled and inoculated into 3 more chick embryos and hemagglutination
looked for after 5 more days.

The chick embryo fibroblast

cultures were checked for hemadsorption of guinea pig erythrocytes
at 3, 5, 7 and 10 days.

43

All attempts at isolation of mumps

virus were negative.
Blood for serologic study was obtained from each animal
previous to inoculation and 4, 6, 8,
90 days after inoculation.

11,

14, 19, 22, 30, 57 and

Serum was separated from clot and

stored at -20°C until used for antibody determination.
Ninety days after the first inoculation with mumps virus,
inoculation of these animals with DA or parainfluenza-3 virus
was carried out.
DA virus.

Monkeys #1 and 2 were given inoculation with

One ml. of monkey kidney tissue culture fluid

containing 10

6 5

TCID per ml. was given intravenously and 1 ml.

16

intranasally to each monkey.

Monkeys #3 and k received similar

amounts of tissue culture fluid containing 10^*5 TCID of
parainfluenza-3 virus.

Blood was collected from each animal

at 5> 8, l4, 21 and 30 days after inoculation.
Monkeys #2 and 3 were given a second inoculation with mumps
virus 6 months after the first and 3 months after the inoculation
with DA in case of #2 and parainfluenza-3 in case of #3 (Table l).
The virus.usedi was the same as that used for the first inoculation

o

having been stored at -70 C.

One ml. was given to each monkey

intravenously and 1 ml. intranasally.
before and 2, 4, 8,

Blood was collected

11, 15, 22 and 30 days after inoculation.

Inoculation of Monkeys #5-7«

Three monkeys which had

previously been inoculated with different viruses were selected
for mumps inoculation to study the response of animals with
known histories of infection.

Monkey #5 had been inoculated

with parainfluenza-1 five months previously; monkey #6 with
polio-1 five months previously; and monkey #7 had received
DA virus ten months and parainfluenza-1 eight months previously
(Table l).

Inoculation with mumps was carried out by intra¬

venous and intramuscular injection of 10' EID of Enders strain
mumps virus per animal (Table l).

Serum was collected before

and 2, U, 7> l4, 21 and 30 days after inoculation.
of illness occurred in these animals.

No signs

Isolation of virus was

not attempted.
Chimpanzee Inoculation with DA Virus.

Stored sera from

chimpanzee (Mack #50) in which DA virus had been inoculated
was furnished by Dr. Hsiung to provide sera representing a

17

primary response to DA virus inoculation.

This animal which

had no pre-existing DA antibodies had been inoculated with DA
virus intravenously.

Antibody Determinations
Hemagglutination-inhibition (Hi) titers were determined
using the viral antigens of the parainfluenza-mumps-NDV group.
The complement fixation test was not used because it has been
found unsuitable for evaluation of activity against DA virus
due to anticomplementary effect when commercial preparations
of complement is used with DA antigen.
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*

Studies in humans

have shown HI and neutralization tests to be more specific than
CF for these viruses.

11

Hemagglutination-inhibition tests were

chosen as it was desired to test large numbers of sera against
several antigens which could be done with one test system; whereas,
both tissue cultures and embryonated eggs would be required to
do neutralization tests against all the viruses concerned.
Hemagglutination-Inhibition Test.
1. Serum Treatment.
56°C for 30 minutes.

Sera were heat inactivated at

Serum agglutinins were removed by adding

packed washed guinea pig erythrocytes to serum diluted 1:5,
keeping the mixture in ice bath for 30 minutes, and then re¬
moving the erythrocytes by centrifugation.

An equal volume

of 2% kaolin in PBS was added to the 1:5 dilution of serum
to remove nonspecific serum inhibitors.

After 20 minutes at

room temperature the kaolin was removed by centrifugation
yielding a 1:10 dilution of serum.
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2.

Antigen Preparation.

Mumps viral antigen

obtained from Lederle (lot number: 2540-36); Parainfluenza-3
and DA were grown in rhesus monkey kidney tissue cultures and
the fluids used for hemagglutinating antigens.

Parainfluenza-3

was grown in presence of SV-5 antisera.
3. Preparation of 0Guinea Pig Erythrocyte Suspension.
Guinea pig erythrocytes were washed three times by suspension
in PBS and centrifugation.

After the third washing the packed

cells were suspended in approximately an equal volume of PBS.
The exact percentage of erythrocytes in this suspension was
determined by use of capillary hematocrit tubes which were
centrifuged in an International microcapillary centrifuge.

The

cell suspension was appropriately diluted to produce a 0.5cl>
suspension in PBS.
4. Test Procedure.

Two-fold dilutions of the treated

serum in 0.2 ml. amounts were made with PBS in plastic cup
panels by use of a serologic diluter.

Two-tenths ml. of

antigen containing 4 hemagglutinating units was added to each
cup.

After one hour at room temperature, 0.4 ml. of the

erythrocyte suspension was added.

The panels were examined

for hemagglutination after two hours.

The HI titer was recorded

as the reciprocal of the highest serum dilution showing no
hemagglutination.

Analysis of Antibody Components
Treatment of Sera with Mecaptoethanol,

Serum was heat

inactivated, serum agglutinins removed with guinea pig
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erythrocytes and. diluted. 1:5 with PBS.

To 0.9 ml. of this

treated serum 0.1 ml. of 1 molar mecaptoethanol (2-ME) in PBS
was added; 0.1 ml. PBS was added to control sera.

The serum

was incubated overnight at 4°C to allow inactivation of 19S
antibody.

After incubation the serum was treated with kaolin

and HI tests performed.
Centrifugation of Sera Across Sucrose Gradient.

Sucrose

gradients were prepared in 5 ml. cellulose nitrate ultracentrifuge
tubes.

The first method used was to layer 0.9 ml. amounts of

sucrose solutions ranging from 37$ on the bottom to 12.5$ on top.
This produced a layered symmetric gradient.

kk

The second type of

gradient used was an asymmetric sucrose gradient prepared by dropwise addition of 40$ sucrose to a 10$ solution.

The asymmetric

gradients were prepared with the apparatus and method of Speir.

kl

Two-tenths ml. of serum, which had been treated with guinea pig
erythrocytes to remove serum agglutinins, was layered over the
gradient.

The gradients were centrifuged for 16.5 hours at

35>000 RPM in a Spinco Model L ultracentrifuge with a SW39
centrifuge head.

After centrifugation, fractions of the gradient

were collected in drops from a needle hole in bottom of the
tube.

Nine fractions of 0.5 ml. were collected from each tube.

Each fraction was diluted 1:2 with PBS.

To 0.5 ml. of each

diluted fraction 0.05 ml. of 1 molar 2-ME was added;
PBS was added to the remaining 0.5 ml.

0.05 ml. of

The fractions were kept

. o
overnight at 4 C before doing antibody determinations.

Absorption of Antibody with Viral Antigens
Antigen Preparations.

1. Mumps--viral antigen obtained
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from Lederle (Lot number: 2540-36) which had hemagglutination
titer of 1:1280 was used.
2. DA virus—tissue culture fluid from monkey kidney cell
tissues infected with DA virus was used for antigen source.

To

1000 ml. of the fluid 20 ml. of packed guinea pig erythrocytes
was added.

Adsorption of virus onto the erythrocytes took place

in 4- hours at room temperature.

The mixture was centrifuged at

1500 PPM for 15 minutes and the supernatant fluid removed.

To

the guinea pig erythrocytes which had virus attached, 50 ml. of
PBS was added.

o

This mixture was kept in 37 C water bath for 1 hour

with intermittent shaking.

After the elution of virus the erythrocytes

were removed by centrifugation and the supernatant used for antigen.
The final antigen solution had hemagglutination titer of 1:1280.
3.

Parainfluenza-3--antigen was prepared from infected

monkey kidney tissue culture by erythrocyte adsorption-elution
as described for DA virus.

The antigen preparation had

hemagglutination titer of 1;640.
A.

Newcastle Disease virus--infected egg fluid with

hemagglutination titer of 1:640 was used (California strain 1191*0*
Absorption of Sera.

Equal volumes of 1:10 dilution of serum

treated as described above in preparation for HI tests and the
1

0

antigen suspension were mixed and kept overnight at 4 C.

The

virus-antibody aggreagates were removed by ultracentrifugation at
40,000 BPM for 4 hours in Spinco Model L ultracentrifuge with No. 40
centrifuge head.

The supernatant fluid was checked for

hemagglutination and treated with guinea pig cells when
necessary to remove agglutinins.
in place of antigen.

To control sera PBS was added
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RESULTS

Antibody Response to First Mumps Inoculation
Monkeys #1-4. (Figures 1-4)

Inoculation of mumps virus

into monkeys #1-4 caused production of mumps HI antibody which
reached maximal levels 19 to 22 days after inoculation in all
four animals.

The antibody levels were first detectible

between 4 and 8 days in low titer.

This low level of initial

antibody production is characteristic of primary response to
a viral infection.

Since these animals were inoculated via

parotid duct or nasopharynx it was assumed that this antibody
response indicated an infection occurred in spite of failure
to isolate mumps virus.

The titers of mumps HI antibody

decreased after 22 to 30 days, but were still significant at
90 days after inoculation.
Only monkey #1 showed a heterologous antibody response to
DA virus after mumps inoculation.

As shown on Figure 1, this

response closely paralleled that of the response to mumps.

All

four animals had initial DA virus HI titers of 40 to 80, yet
only one showed a heterologous response.

None of the animals

responded with a rise of parainfluenza-3 HI antibody.

High

levels of antibody against parainfluenza-3 were present at the
time of mumps inoculation.
Monkeys #5-7.

(Figures 5-7)

These monkeys which were

inoculated by intravenous and intramuscular injection of Enders
strain of mumps virus responded with a rise of mumps antibody
less pronounced than that seen in monkeys #1-4.

Monkey #6

had initial mumps HI titer of 40 while the other two had titers
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of 10.

The presence of pre-existing antibodies indicates the

probability in one, and perhaps all three, of previous
experience with mumps virus.
None of the animals showed heterologous response with
antibodies to DA virus or parainfluenza-3 to which they had
significant pre-existing HI antibody titers.

Antibody Response to DA Inoculation
Monkeys #1 and 2.

(Figures 1 & 2)

Inoculation of DA

virus was followed by a rise in DA virus HI antibodies in
both animals.

This rise was marked at 5 days and reached

maximal level at 8 days.

The rapidity and magnitude of this

response are characteristic of a secondary, or anamnestic,
antibody response.
Both monkeys showed an eight-fold heterologous rise in
HI antibody to mumps after DA Inoculation.

This response was

of less magnitude than that seen after the first mumps inoculation,
but was of similar temporal progression.

Monkey #1 showed a

four-fold increase in HI antibody to parainfluenza-3 after
DA virus.

Antibody Response to Parainfluenza-3 Inoculation
Monkeys #3 and 1+.

(Figures 3 & 4)

Monkey #3 which had HI

titer of 1280 against parainfluenza-3 at the time of inoculation
showed no significant response to this virus.

Monkey jjh which

had initial titer of 160 showed a rapid response characteristic
of an anamnestic rise.
A four-fold increase in DA titer was seen in monkey #3>
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but no significant heterologous response in monkey #4.
Neither animal showed a heterologous response against mumps.

Antibody Response to Second Mumps Inoculation
Monkeys #2 and 3»

(Figures 2 & 3)

Both monkeys showed an

increase in mumps HI titer of more than 100-fold by eight days.
At the time of this inoculation, both animals had low levels
of mumps HI antibody which had persisted since first mumps
inoculation six months previously.
Neither animal showed an increase in DA virus HI antibody
titers.

The sera from these monkeys were also tested for

antibodies against parainfluenza-2 and NDV; no antibodies to
these viruses were found.

Sensitivity of HI Antibodies to 2-ME Treatment
The antibody titers of sera after treatment with 2-ME
are shown on Figures 1-7.

A two-fold or greater decrease in

HI antibody titer against mumps is seen in all sera tested
from monkeys #1-4 during the first fourteen days after
inoculation (Figures 1-4).

This is further evidence that

these animals experienced a primary infection witn mumps.

A

two to four-fold decrease after 2-ME treatment is seen in
sera obtained 2, 4 and 7 days after mumps inoculation,from
monkeys #5 and 7> But not from #6 which had higher pre-existing
antibodies and less response to inoculation.

A decrease in mumps

titer with 2-ME treatment is also seen in sera from monkeys #1
and 2 taken during the period of heterologous antibody rise
following DA inoculation (Figures 1 & 2).

The titer of mumps

2k

antibody following a second inoculation with mumps was not
decreased by 2-ME treatment (Figure

2). ; }.

As shown in Figures 1-7, DA virus and parainfluenza-3
antibody titers were found not to be affected by 2-ME
treatment in all these sera tested.

None of these sera

represented a primary inoculation, although both homologous
and heterologous rises were seen in the groups tested.
from chimpanzee

Sera

which had an HI titer of 20 three days

after primary DA inoculation was treated with 2-ME; antibody
activity could no longer be detected at 1 to 10 dilution (not
shown in figures).

Results of Separation of 19S and 7S Antibodies by Sucrose
Gradient Centrifugation
Because of the inability of 2-ME treatment to detect 19S
antibody in the presence of greater amounts of 7S antibody,
certain sera were centrifuged across sucrose gradients to
separate 19S from 7S antibodies.
are shown in Figures 8-l6.

The results of centrifugation

The hemagglutination-inhibiting

activity of each fraction is indicated as the reciprocal of
the highest dilution of the fraction giving complete inhibition
in the system described for antibody determination.

This HI

activity represents the HI antibody present in each fraction,
but does not represent the actual serum antibody titer because
the dilution in each fraction depends upon the sedimentation
properties of the antibodies.

The recorded titers indicate

the relative amount of HI antibody in each fraction.

The

findings shown in Figures 8-l6 indicate that the 2-ME labile
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activity--19S antibody--is limited to the lower fractions,
whereas 2-ME stable activity--7S antibody-- is concentrated in
the higher fractions.
Activity of serum from monkey §1 eight days after first
mumps inoculation is shown in Figure 8.

All mumps antibody

was in the bottom fraction, whereas all DA activity is in
fractions 5-7*

The antibody against mumps was all destroyed

by 2-ME, whereas that against DA virus was not.

These findings

confirm those presented above ( Figure l) that soon after mumps
inoculation 19S antibody against mumps is present, but not against
DA virus.

In contrast, serum taken 90 days after mumps inoculation

and just before DA inoculation had no 19S antibody (Figure 9).
As shown in Figure 1, monkey #1 had a rise to mumps
following DA inoculation.

It is also shown on Figure 1, that

there was a decrease in mumps antibody, but not DA antibody,
after 2-ME treatment of serum obtained 8 days after DA
inoculation.

The results of centrifugation of this sera

obtained during the period of homologous DA rise and
heterologous mumps rise are shown in Figures 10 and 11.

Both

figures show 2-ME labile antibody to mumps virus, but better
separation of the 2-ME labile--19S--antibody and 7S antibody
is seen in Figure 11 which shows the results when the asymmetric
gradient was used.

A two-fold decrease in activity of DA

antibody was seen in the bottom three fractions with the
sample centrifuged in the asymmetric gradient (Figure ll), but
not that in the symmetric gradient (Figure 12).
Serum from monkey #2 obtained Ik days after first mumps
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inoculation showed 19S and JS antibody to mumps, but only 7S
to DA virus (Figure 12).

Figures 13 and l4 show the results

of centrifugation of serum from monkey #2 taken 8 days after
DA inoculation.

The results are similar to those for monkey #1

taken 8 days after DA inoculation.

Comparing Figure 13 to

Figure 11, it can be seen that both show decrease in DA activity
after 2-ME treatment of the lower three fractions, better seen
with sera from monkey $2 than jfl.

In both animals tested

heterologous rise in mumps antibody after DA inoculation was
accompanied by 19S mumps antibody production.
Figures 15 and l6 show the results of centrifugation of
serum from monkey #2 during a secondary response to mumps
virus.

The presence of 19S is shown by the four-fold decrease

in titer seen in fraction 1 of the asymmetric gradient after
treatment with 2-ME,

The great amount of 7S present in this

sera almost obliterates the 19S peak which can be demonstrated
only in the bottom fraction of the asymmetric gradient.
By use of sucrose gradients the presence of 19S antibody
in the secondary response of monkeys to mumps and DA virus
could be demonstrated, although amounts of 19S were too small
for detection with 2-ME.

Further 19S antibody against mumps

was shown to be produced in response to DA inoculation.

No

19S DA antibody was seen in response to primary or secondary
mumps inoculation.

The asymmetric gradients were shown in

the three instances used to be superior to the symmetric gradients*
for separation of 19S and 7S activity of the serum samples used.
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Antibody Absorption by Viral Antigens
Results of absorption by mumps, DA, parainfluenza-3 and
NDV antigens of sera obtained from the seven monkeys and
chimpanzee #50 are shown in Tables 2 and 3*

The sera used

represent the following antibody responses:

1) early and late

primary mumps inoculation, i.e.

11,

l4 and 22 days following

first mumps inoculation in monkeys #1-4, 2) heterologous mumps
response to DA inoculation,

i.e. 8 days following DA inoculation

in monkeys #1 and 2, 3) secondary mumps inoculation, i.e.

11 days

after second mumps inoculation in monkeys #2 and 3? 4) primary
inoculation with DA, i.e. chimpanzee #50,

5) response to DA

inoculation in monkeys with pre-existing DA antibodies,

i.e.

monkeys #1 and 2, sera from 8 days after DA inoculation, 6)
heterologous DA rise in response to mumps, i.e. monkey #1,
sera from 22 days after first mumps inoculation.
In all instances specific antibody was completely removed
or greatly reduced in titer by absorption with the homologous
virus.

Regardless of the virus used to stimulate antibody

production manifest in a given serum sample, no significant
decrease in titer of antibody against any virus other than
that used for absorption was seen.
To rule out the possibility that failure to demonstrate
cross absorption was due to insufficient amount of antigen, a
second absorption procedure was carried out.

This was done

after the sera was shown free of antibody against the virus
used for absorption.

No decrease in heterologous antibody

occurred with this further absorption.

28
DISCUSSION

Studies cited in Beview of Literature of antigenic
cross reactivity between these viruses have been of two types:
1) survey of populations for antibodies against these viruses,
with or without concomitant attempts at virus isolation, and
2) studies of the immunological response of laboratory animals
Inoculated with one or more of these agents.
first type offer disadvantages that:

Studies of the

1) the infecting agent

cannot always be known with certainty, 2) possibility of
multiple infection cannot be eliminated,

3) previous experience

with agents is difficult to evaluate, k) host factors cannot be
evaluated or controlled,

5) mode of infection is not controlled,

6) changes may occur in viral properties as virus undergoes
uncontrolled passage in the environment.

Studies with laboratory

animals eliminate some of these disadvantages, but conclusions
from these studies must be applied to consideration of human
infections with caution.
The high rate of natural infections of captive monkeys
with parainfluenza-3 and -5 was confirmed in these studies.
Of particular note in monkeys jfl-b was the high initial titers
against parainfluenza-3.

These titers decreased somewhat over

the course of the study and may indicate the animals had
acquired natural infection with this virus shortly before their
use in these experiments, a similar circumstance to that found by
Churchill.

12

The high level of parainfluenza-3 antibody makes

heterologous response to this virus difficult to evaluate.
Because all animals used had pre-existing titers to these
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viruses, whether or not previous experience with one of these
viruses is necessary to show a heterologous response could
not be evaluated directly.

It was shown that a heterologous

response does not always occur even when pre-existing anti¬
bodies are present, but varies from individual to individual.
Because of the widespread occurrence in laboratory animal
populations of the viruses under study it is difficult to
evaluate previous viral infections in the individual animals
used.
Cross reactivity in terms of ability to evoke heterologous
antibody responses to members of the parainfluenza-mumps-KDV
group has been shown to occur.

One animal in seven showed a

rise in DA. antibody with mumps infection; both animals inoculated
with DA virus showed mumps rise.

One of two animals inoculated

with parainfluenza-3 responded with rise to DA.
earlier other workers have found extensive,

As cited

inconsistant cross

reactivity among these viruses.
The findings that 19S antibody is present early in primary
infection and that 7S persists long after disappearance of
19S are in keeping with the work of others already cited.

The

presence of small amounts of 19S in secondary response to
viral inoculation is in agreement with the findings of Svehag
and Mandel that 19S antibody, in much smaller amounts than 7S,
is found in anamnestic response.
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The data presented also show- that 19S antibody was
produced against mumps in response to DA virus inoculation.
At the time DA virus was inoculated only 7S mumps antibody
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was present.

Other workers have postulated on the basis of

their findings that presence of antigen is necessary for 19S
production.50

According to this theory 19S antibody

formation occurs only while there is persistance of antigen,
rapidly falling off after loss of antigenic stimulus.

The

presence of 19S mumps antibody after DA inoculation vould
indicate, according to this theory, that mumps antigen may
be present.

Many viral infections, including mumps, have

been shown to persist for several months in a quiescent state.
While this cannot be definitely ruled out, absence of 19S
antibody just before DA inoculation makes it less likely.

The

other possibility in keeping with this theory is that DA virus
provides the necessary antigenic stimulus for 19S mumps antibody
production.

This explanation implies the presence of a common

structural antigenic component shared by these two viruses which
is important in providing a stimulus for mumps HI antibody
production.
To evaluate this possibility that the heterologous antibody
responses were due to common antigenic components shared by
members of the parainfluenza-mumps-NDV group, absorption studies
were carried out.

The data presented show that HI antibody

against mumps, DA or parainfluenza-3 will not react with either
of the other two or NDV.

Thus, the mumps antibody which was

caused to increase in titer by DA virus could not be absorbed
with DA virus.

These studies indicate that common antigenic

components could not be the explanation for the cross reactivity
occurring between these viruses.
The evidence presented would question whether or not
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persistence of antigen is necessary in all cases for
production of 19S antibody.

The real significance of heter¬

ologous 19S antibody cannot be stated.

A heterologous rise

to DA following mumps inoculation in monkey #1 was not accompanied
by detectible 19S production.
Several workers have suggested the importance of host
factors in determining whether or not a heterologous response
will occur.

The factor which has been suggested is previous

experience with the virus, a heterologous response representing
11 23 32 4o
a special type of anamnestic antibody response.' ’
’
’

The

data presented in this thesis are consistant with this theory,
but do not offer proof that the pre-existing antibodies are a
necessary factor.

There must, however, also be viral factors

operative in the production of a heterologous response, for
a response against one of these agents is evoked by other
members of this group.

Thus, some factor--other than shared

antigens--must be present during an infection with one of the
parainfluenza-mumps-NDV viruses which causes the individual to
react by producing heterologous antibody in certain cases.

The

delineation and relative importance of these viral and host
factors awaits further investigation.
Certain points can be inferred from the data presented.
A rise in antibody against one of the agents studied may
result from infection with another one of these agents;
therefore, serologic diagnosis alone is inadequate.

Demonstration

of 19S antibody alone is not proof of a primary response, as 19S
antibody may be found in a secondary response or a response
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initiated by a virus other than that to which the specific
19S antibody is found.

The ability of a virus to cause

production of heterologous antibody does not necessarily
mean it shares antigens with the heterologous virus, or that
the antibody produced will react with the virus causing its
production.

Failure of cross reactivity of antibodies to these

viruses, along with the evidence that pre-existing experience
with a virus is a factor determining heterologous response,
make it seem unlikely that significant cross protection is
afforded by infection with one of these viruses.
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SUMMARY

Cross reactivity as shown by heterologous antibody
response in monkeys was demonstrated between mumps, DA and
parainfluenza-3 viruses.

Presence of 19S antibodies was

demonstrated to mumps after primary and secondary mumps
inoculation and after DA inoculation which resulted in a
mumps antibody rise.

After mumps inoculation,

19S antibody

to DA was not present although one animal showed DA
antibody rise, but 19S antibody was present after DA
inoculation.

Absorption of sera with mumps, DA, parainfluenza

and NDV antigens showed no cross absorption of any antibody
present.

Thus,

it was shown that cross reactivity as expressed

in ability to evoke a heterologous antibody response was not
associated with common antigens which could be demonstrated
by absorption in the parainfluenza-mumps-MDV group of myxoviruses.

3^

Animal
No.

Virus

Second
Inoculation
Months
after
Virus
first

1

Mumps

DA

3

2

Mumps

DA

3

Mumps

k

First
Inoculation

Third
Inoculation

Months
Virus

after
second

3

Mumps

3

Para-3

3

Mumps

3

Mumps

Para-3

3

5

Para-1

Mumps

5

6

Polio-1

Mumps

7

DA

Para-1

Mumps

8

Table 1.

5
2

Sequence of virus inoculations in Rhesus monkeys

Table 2.
Results of antibody absorption of sera from
monkeys fl-b.

Table 3*

Results of antibody absorption of sera from

monkeys #5"7»
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Figure 3.
Monkey #3.
inoculations.
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Figure #4.
Monkey #4.
inoculations.
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HI antibody titers following virus
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Figure 5.
Monkey #5inoculation.
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HI antibody titers following mumps
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Figure 6.
Monkey #6.
inoculation.

HI antibody titers following mumps
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Figure 7.
Monkey
inoculation.
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#7.

HI antibody titers following mumps
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Figure 8
Monkey #1 eight days after first mumps inoculation.
Fractionation of serum in symmetric sucrose gradient.

BOTTOM

FRACTION

NUMBER

TOP

Figure 9.
Monkey #1 ninety days after first mumps inoculation.
Fractionation of serum in symmetric sucrose gradient.

BOTTOM

FRACTION

NUMBER

TOP

Figure 10.
Monkey $1 eight days after DA inoculation.
Fractionation of serum in symmetric sucrose gradient.

Figure 11.
Monkey #1 eight days after DA inoculation.
Fractionation of serum in assymmetric sucrose gradient.
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Figure 12.
Monkey #2 fourteen days after first mumps inoculation.
Fractionation of serum in symmetric sucrose gradient.

<r>

FRACTION

NUMBER

Figure 13.
Monkey #2 eight days after DA inoculation.
Fractionation of serum in symmetric sucrose gradient.

Figure Ik.
Monkey #2 eight days after DA inoculation
Fractionation of serum in asymmetric sucrose gradient.
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Figure 1J.
Monkey $2 eight days after second mumps inoculation.
Fractionation of serum in symmetric sucrose gradient.

Figure 16.
Monkey #2 eight days after second mumps inoculation.
Fractionation of serum in asymmetric sucrose gradient.
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